{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T10:27:50Z","timestamp":1793528870087,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euo.2026.03.007","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:36:02Z","timestamp":1775151362000},"page":"1171-1183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-0082","authenticated-orcid":false,"given":"Arthur","family":"Peyrottes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"de Brek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Vieira Aleixo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Baboudjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Anract","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Olivier","family":"Timsit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"M\u00e9jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Emmanuel","family":"Guidotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dariane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.03.007_b0005","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.2174\/1381612824666180404152304","article-title":"Comparative assay of 2D and 3D cell culture models: proliferation, gene expression and anticancer drug response","volume":"24","author":"Souza","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.euo.2026.03.007_b0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.2451290","article-title":"Cell and environment interactions in tumor microregions: the multicell spheroid model","volume":"240","author":"Sutherland","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.euo.2026.03.007_b0015","first-page":"1116","article-title":"Multicellular tumor spheroids of LNCaP-Luc prostate cancer cells as in vitro screening models for cytotoxic drugs","volume":"12","author":"Jouberton","year":"2022","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.euo.2026.03.007_b0020","doi-asserted-by":"crossref","first-page":"6806","DOI":"10.3390\/ijms21186806","article-title":"Three-dimensional cell cultures as an in vitro tool for prostate cancer modeling and drug discovery","volume":"21","author":"Fontana","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euo.2026.03.007_b0025","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41591-024-03489-3","article-title":"Clinical applications of human organoids","volume":"31","author":"Verstegen","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2026.03.007_b0030","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1158\/2159-8290.CD-16-1154","article-title":"Personalized in vitro and in vivo cancer models to guide precision medicine","volume":"7","author":"Pauli","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.euo.2026.03.007_b0035","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41585-022-00677-z","article-title":"Experimental in vitro, ex vivo and in vivo models in prostate cancer research","volume":"20","author":"Sailer","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2026.03.007_b0040","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169616","article-title":"Prostate organoids: emerging experimental tools for translational research","volume":"133","author":"Beshiri","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.euo.2026.03.007_b0045","unstructured":"European Medicine Agency. Guideline on the principles of regulatory acceptance of 3Rs (replacement, reduction, refinement) testing approaches. Published Online 2017. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-principles-regulatory-acceptance-3rs-replacement-reduction-refinement-testing-approaches_en.pdf."},{"key":"10.1016\/j.euo.2026.03.007_b0050","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/aor.14503","article-title":"FDA Modernization Act 2.0 allows for alternatives to animal testing","volume":"47","author":"Han","year":"2023","journal-title":"Artif Organs"},{"key":"10.1016\/j.euo.2026.03.007_b0055","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.euo.2026.03.007_b0060","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s43586-022-00174-y","article-title":"Organoids","volume":"2","author":"Zhao","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"10.1016\/j.euo.2026.03.007_b0065","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2026.03.007_b0070","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.euo.2026.03.007_b0075","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr Biol"},{"key":"10.1016\/j.euo.2026.03.007_b0080","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1038\/onc.2008.271","article-title":"The tumor microenvironment and its role in promoting tumor growth","volume":"27","author":"Whiteside","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.euo.2026.03.007_b0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-cancerbio-030518-055702","article-title":"Organoid models for cancer research","volume":"3","author":"Clevers","year":"2019","journal-title":"Annu Rev Cancer Biol"},{"key":"10.1016\/j.euo.2026.03.007_b0090","doi-asserted-by":"crossref","unstructured":"Dolgos R, Parmentier R, Wang J, et al. ECM-free patient-derived organoids preserve diverse prostate cancer lineages and uncover in vitro-enriched cell types. bioRxiv. https:\/\/doi.org\/10.1101\/2024.10.16.618617.","DOI":"10.1101\/2024.10.16.618617"},{"key":"10.1016\/j.euo.2026.03.007_b0095","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3390\/biom11111572","article-title":"Modeling prostate cancer treatment responses in the organoid era: 3D environment impacts drug testing","volume":"11","author":"Van Hemelryk","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.euo.2026.03.007_b0100","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1021\/mp500085p","article-title":"Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening","volume":"11","author":"Fong","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.euo.2026.03.007_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119402","article-title":"Microenvironment engineering of osteoblastic bone metastases reveals osteomimicry of patient-derived prostate cancer xenografts","volume":"220","author":"Shokoohmand","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.euo.2026.03.007_b0110","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3892\/ol.2021.13124","article-title":"Establishment and characterization of prostate organoids from treatment-na\u00efve patients with prostate cancer","volume":"23","author":"Cheaito","year":"2022","journal-title":"Oncol Lett"},{"key":"10.1016\/j.euo.2026.03.007_b0115","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/1878-0261.13382","article-title":"Preclinical patient-derived modeling of castration-resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease","volume":"17","author":"Elsesy","year":"2023","journal-title":"Mol Oncol"},{"key":"10.1016\/j.euo.2026.03.007_b0120","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1038\/s41467-018-04495-z","article-title":"Patient derived organoids to model rare prostate cancer phenotypes","volume":"9","author":"Puca","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.03.007_b0125","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2014.08.016","article-title":"Organoid cultures derived from patients with advanced prostate cancer","volume":"159","author":"Gao","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.euo.2026.03.007_b0130","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-17-3571","article-title":"Targeting bromodomain and extra-terminal (BET) family proteins in castration-resistant prostate cancer (CRPC)","volume":"24","author":"Welti","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.03.007_b0135","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00432-018-2803-5","article-title":"Patient-derived, three-dimensional spheroid cultures provide a versatile translational model for the study of organ-confined prostate cancer","volume":"145","author":"Linxweiler","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.euo.2026.03.007_b0140","doi-asserted-by":"crossref","unstructured":"Beshiri ML, Capaldo BJ, Lake R, et al. The origin and dynamics of cellular heterogeneity vary across lineage subtypes of castrate resistant prostate cancer. bioRxiv. https:\/\/doi.org\/10.1101\/2022.03.24.484651.","DOI":"10.1101\/2022.03.24.484651"},{"key":"10.1016\/j.euo.2026.03.007_b0145","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/path.5698","article-title":"Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens","volume":"254","author":"Servant","year":"2021","journal-title":"J Pathol"},{"key":"10.1016\/j.euo.2026.03.007_b0150","doi-asserted-by":"crossref","first-page":"473","DOI":"10.48095\/ccko2022473","article-title":"Advantages and limitations of 3D organoids and ex vivo tumor tissue culture in personalized medicine for prostate cancer","volume":"35","author":"Mickova","year":"2022","journal-title":"Klin Onkol"},{"key":"10.1016\/j.euo.2026.03.007_b0155","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2021.03.023","article-title":"Generating human prostate cancer organoids from leukapheresis enriched circulating tumor cells","volume":"150","author":"Mout","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2026.03.007_b0160","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.actbio.2024.02.025","article-title":"Bone mimetic environments support engineering, propagation, and analysis of therapeutic response of patient-derived cells, ex vivo and in vivo","volume":"178","author":"Paindelli","year":"2024","journal-title":"Acta Biomater"},{"key":"10.1016\/j.euo.2026.03.007_b0165","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.euo.2023.10.011","article-title":"Development of novel models of aggressive variants of castration-resistant prostate cancer","volume":"7","author":"Bigot","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.03.007_b0170","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe1505","article-title":"Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets","volume":"376","author":"Tang","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.euo.2026.03.007_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110595","article-title":"Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis","volume":"39","author":"Han","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.euo.2026.03.007_b0180","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12032-021-01582-y","article-title":"Live cell molecular analysis of primary prostate cancer organoids identifies persistent androgen receptor signaling","volume":"38","author":"Heninger","year":"2021","journal-title":"Med Oncol"},{"key":"10.1016\/j.euo.2026.03.007_b0185","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1158\/0008-5472.CAN-21-3360","article-title":"HER3 is an actionable target in advanced prostate cancer","volume":"81","author":"Gil","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2026.03.007_b0190","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/s41467-021-21300-6","article-title":"Patient-derived xenografts and organoids model therapy response in prostate cancer","volume":"12","author":"Karkampouna","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.03.007_b0195","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.3390\/cells11223632","article-title":"Patient-derived xenografts and organoids recapitulate castration-resistant prostate cancer with sustained androgen receptor signaling","volume":"11","author":"Van Hemelryk","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.euo.2026.03.007_b0200","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13000-024-01511-3","article-title":"Rare histologic transformation of a CTNNB1 (\u03b2-catenin) mutated prostate cancer with aggressive clinical course","volume":"19","author":"Akhoundova","year":"2024","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.euo.2026.03.007_b0205","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1158\/1078-0432.CCR-21-3603","article-title":"Acetylated HOXB13 regulated super enhancer genes define therapeutic vulnerabilities of castration-resistant prostate cancer","volume":"28","author":"Nguyen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.03.007_b0210","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/1878-0261.12354","article-title":"A patient-derived explant (PDE) model of hormone-dependent cancer","volume":"12","author":"Centenera","year":"2018","journal-title":"Mol Oncol"},{"key":"10.1016\/j.euo.2026.03.007_b0215","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/path.6149","article-title":"Club-like cells in proliferative inflammatory atrophy of the prostate","volume":"261","author":"Huang","year":"2023","journal-title":"J Pathol"},{"key":"10.1016\/j.euo.2026.03.007_b0220","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/s41388-024-03005-4","article-title":"DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer","volume":"43","author":"Guo","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.euo.2026.03.007_b0225","doi-asserted-by":"crossref","first-page":"14672","DOI":"10.1038\/s41598-018-33055-0","article-title":"Drug screening of biopsy-derived spheroids using a self-generated microfluidic concentration gradient","volume":"8","author":"Mulholland","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2026.03.007_b0230","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1038\/s41467-021-25175-5","article-title":"The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology","volume":"12","author":"Risbridger","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.03.007_b0235","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/24725552211020668","article-title":"High-throughput imaging assay for drug screening of 3D prostate cancer organoids","volume":"26","author":"Choo","year":"2021","journal-title":"SLAS Discov"},{"key":"10.1016\/j.euo.2026.03.007_b0240","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade5855","article-title":"Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer","volume":"15","author":"Wang","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.euo.2026.03.007_b0250","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910659","article-title":"The novel BET-CBP\/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer","volume":"11","author":"Yan","year":"2019","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.euo.2026.03.007_b0255","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/nm.4378","article-title":"Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4","volume":"23","author":"Dai","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2026.03.007_b0260","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.3390\/ijms25158543","article-title":"Anti-cancer properties of two intravenously administrable curcumin formulations as evaluated in the 3D patient-derived cancer spheroid model","volume":"25","author":"Niederreiter","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euo.2026.03.007_b0265","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/s41416-024-02810-8","article-title":"CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer","volume":"131","author":"Rahman","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2026.03.007_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106692","article-title":"Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models","volume":"189","author":"Xu","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.euo.2026.03.007_b0275","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1158\/0008-5472.CAN-23-0883","article-title":"Prostate cancer progression relies on the mitotic kinase citron kinase","volume":"83","author":"Rawat","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2026.03.007_b0280","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202001594","article-title":"Patient-derived prostate cancer explants: A clinically relevant model to assess siRNA-based nanomedicines","volume":"10","author":"Tieu","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.euo.2026.03.007_b0285","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41420-025-02505-w","article-title":"Breakthroughs and challenges of organoid models for assessing cancer immunotherapy: a cutting-edge tool for advancing personalized treatments","volume":"11","author":"Wang","year":"2025","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.euo.2026.03.007_b0290","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1016\/j.apsb.2025.04.031","article-title":"Immune organoid for cancer immunotherapy","volume":"15","author":"Wang","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.euo.2026.03.007_b0295","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.euo.2021.02.008","article-title":"A systematic review of prostate cancer heterogeneity: understanding the clonal ancestry of multifocal disease","volume":"4","author":"Erickson","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.03.007_b0300","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/pros.24682","article-title":"Defining the challenges and opportunities for using patient\u2010derived models in prostate cancer research","volume":"84","author":"Brennen","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2026.03.007_b0305","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrurol.2017.65","article-title":"The potential of organoids in urological cancer research","volume":"14","author":"Wang","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2026.03.007_b0310","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.2174\/1381612825666190308150055","article-title":"Human-derived organ-on-a-chip for personalized drug development","volume":"24","author":"Jodat","year":"2018","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.euo.2026.03.007_b0315","doi-asserted-by":"crossref","unstructured":"Xue C, Sun F, Zhu H, et al. Advancements, strategies, and challenges in organoid-based drug evaluation for tissue engineering and regenerative medicine. Engineering, in press. https:\/\/doi.org\/10.1016\/j.eng.2025.10.013.","DOI":"10.1016\/j.eng.2025.10.013"},{"key":"10.1016\/j.euo.2026.03.007_b0320","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/pros.23745","article-title":"Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response","volume":"79","author":"Zhang","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2026.03.007_b0325","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.ajpath.2019.02.017","article-title":"Functional organotypic cultures of prostate tissues: a relevant preclinical model that preserves hypoxia sensitivity and calcium signaling","volume":"189","author":"Figiel","year":"2019","journal-title":"Am J Pathol"},{"key":"10.1016\/j.euo.2026.03.007_b0330","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/0008-5472.CAN-21-0799","article-title":"A microfluidic cancer-on-chip platform predicts drug response using organotypic tumor slice culture","volume":"82","author":"Chakrabarty","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2026.03.007_b0335","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/s41598-023-29065-2","article-title":"Tumor organoid biobank-new platform for medical research","volume":"13","author":"Xie","year":"2023","journal-title":"Sci Rep"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T09:32:28Z","timestamp":1793525548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126000684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2588931126000684"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.03.007","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}